Table 1.
Patients and disease characteristics in the study population
| Characteristics | Study population (N=331) n (%) |
| Age (years) | |
| Median | 60 |
| IQR | (47-70) |
| Sex | |
| Female | 151 (45.6) |
| Male | 180 (54.4) |
| ECOG PS | |
| 0 | 167 (50.5) |
| ≥ 1 | 164 (49.5) |
| Primary tumor location | |
| Right colon | 222 (67.1) |
| Left colon/rectum | 109 (32.9) |
| Primary tumor resection | |
| Yes | 268 (81.0) |
| No | 63 (19.0) |
| RAS and BRAF mutational status | |
| RAS mutated | 103 (31.1) |
| BRAF mutated | 89 (26.9) |
| All wild-type | 127 (38.4) |
| Unknown | 12 (3.6) |
| Time to metastases | |
| Synchronous | 162 (48.9) |
| Metachronous | 169 (51.1) |
| Metastatic sites (N) | |
| 1 | 158 (47.7) |
| >1 | 173 (52.3) |
| Previous treatment for metastatic disease | |
| Yes | 260 (78.5) |
| No | 71 (21.5) |
| Choice of ICI regimen | |
| Anti-PD-(L)1 monotherapy | 239 (72.2) |
| Anti-PD-1 plus anti-CTLA-4 combo | 92 (27.8) |
CTLA-4, cytotoxic T-lymphocyte antigen 4; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; PD-(L)1, programmed death- (ligand)1.